Clinical Trial Update: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating tucatinib, palbociclib, and letrozole in metastatic hormone receptor-positive and HER2-positive breast cancer has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Palbociclib (palbociclib)
• Tucatinib (tucatinib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-27